DATE: January 9, 2002 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6753.US.02	SERIAL NO. 09/985,974
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) Jorge D. Brioni	
(Use several sheets if necessary)	FILING DATE November 7, 2001	GROUP 1614
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
MB	A1	3,428,728	2/18/69				
MB	A2	5,714,487	2/3/98	Sanner			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

MB	C1	Altar, C.A. et al., *"Dopamine Release and Metabolism after Chronic Delivery of Selective or Nonselective dopamine Autoreceptor Agonists,"* Molecular Pharmacology 33:690-695 (1988)
	C2	Andersson, K.E. et al., *"Physiology of Penile Erection,"* Physiological Reviews 75(1):191-236 (1995)
	C3	Berge, S.M. et al., *"Pharmaceutical Salts,"* Journal of Pharmaceutical Sciences 66(1):1 et Seq. (1977)
	C4	Chio, C.L. et al., *"Activation of Heterologously expressed D3 Dopamine Receptors: comparison with D2 Dopamine Receptors,"* Molecular Pharmacology 45:51-60 (1994)
	C5	DeGroat, W. et al., " Neural Control of Penile Erection, in: Nervous control of urogenital system," Vol. 3467-524 (1993)
	C6	Fray, P.J., et al., *"An Observational Method for Quantifying the Behavioural effects of Dopamine Agonists: Contrasting Effects of d-Amphetamine and Apomorphine,"* Psychopharmacology 69(3):253-259 (1980)
	C7	Gazi, et al., Arch Pharmacol 361:555-564 (2000)
	C8	Glase, S.A. et al., *"Substituted [(4-Phenylpiperazinyl)-methyl]benzamides: Selective Dopamine D_4 Agonists,"* J. Med. Chem. 40:1771-1772 (1997)
	C9	Grandy, D.K. et al., *"Cloning of the cDNA and gene for a human D_2 dopamine receptor,"* Proc. Natl. Acad. Sci 86:9762-9766 (1989)
	C10	Keating, D.E., et al., *"Efficacy and Safety of Fixed-Dose and Dose-Optimization Regimens of Sublingual Apomorphine Versus Placebo in men with Erectile Dysfunction"* Urology, 56(1):130-135 (2000)
	C11	Milligan, G. et al., *"Chimaeric Gα proteins: their potential use in drug discovery,"* Trends Pharmacol Sci., 20:118-124 (1999)
	C12	Missale, C., et al., *"Dopamine Receptors: From structure to Function,"* Physiol. Rev. 78:189-225 (1998)
	C13	Moller, H.G. et al., *"conditioning of pre- and post-synaptic behavioural responses to the dopamine receptor agonist apomorphine in rats,"* Psychopharmacology 91:50-55 (1987)
MB	C14	Morales, A. et al., *"Oral and topical treatment of erectile dysfunction,"* Urologic Clinics of North America 22(4) 879-886 (1995)

09/03/02

MD	C15	Moreland, R.B., *"Prospectives for pharmacotherapy of male erection,"* Current Opinion in CPNS Investigational Drugs, 2(3):283-302 (2000)
	C16	Padma-Nathan, H. et al., *"Efficacy and Safety of Apomorphine SL vs Placebo for Male Erectile Dysfunction (MED),"* Journal of Urology 161:214 Abstract 821 (1999)
	C17	Primus, R.J. et al., *"Localization and characterization of Dopamine D_4 Binding Sites in Rat and Human Brain by Use of the Novel, D_4 Receptor-Selective Ligand [^{3}H]NGD 94-1,"* Journal of Pharmacology and Experimental Therapeutics 282(2):1020-1027 (1997)
	C18	Suzuki, M. et al., *"D_3 dopamine receptor mRNA is widely expressed in the human brain,"* Brain Research 779:58-74 (1998)
	C19	Vallone, D. et al., *"Structure and function of dopamine receptors,"* Neuroscience and Biobehavioral Reviews 24:125-132 (2000)
	C20	Van Tol et al., *"Multiple dopamine D4 receptor variants in the human population,"* Nature, 358:149-152 (1992)
MD	C21	Zorn, S.H., et al., *"A Selective Dopamine D4 Receptor Agonist,"* Society for Neuroscience, 23:685 (1997)

EXAMINER	**DATE CONSIDERED** 2/10/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)